<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article104</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/EMPA-REG_OUTCOME" style="display:block; margin-bottom:10px;">EMPA-REG OUTCOME Original</a></li>
<h2><strong>EMPA-REG OUTCOME</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Empagliflozin in High Cardiovascular Risk Patients with Type 2 Diabetes".The New England Journal of Medicine. 2015.<br/>
<br/>
### Clinical Question<br/>
Does the addition of empagliflozin to standard care in patients with type 2 diabetes at high risk of cardiovascular events improve cardiovascular outcomes?<br/>
<br/>
### Bottom Line<br/>
Among patients with type 2 diabetes at high cardiovascular risk, empagliflozin added to standard care resulted in a lower rate of cardiovascular deaths and reduced deaths from any cause compared to placebo.<br/>
<br/>
### Major Points<br/><br/>
<br/>
### Guidelines<br/>
As of the publication of this trial, specific guidelines for the inclusion of empagliflozin in the management of patients with type 2 diabetes at high cardiovascular risk had not been established.<br/>
<br/>
### Design<br/>
- Multicenter, randomized, double-blind, placebo-controlled trial<br/>
- N=7,020 patients with type 2 diabetes and high cardiovascular risk<br/>
- Interventions:<br/>
  - Empagliflozin 10 mg (n=2,345) <br/>
  - Empagliflozin 25 mg (n=2,342)<br/>
  - Placebo (n=2,333)<br/>
- Primary outcome: composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke<br/>
- Median follow-up: 3.1 years<br/>
<br/>
### Population<br/>
- Inclusion criteria: Adults ≥18 years old, BMI ≤45, eGFR ≥30 mL/min/1.73 m², established cardiovascular disease, baseline A1C 7-9% naive to glucose-lowering agents or on stable therapy with A1C 7-10%<br/>
- Exclusion criteria: Symptomatic ventricular arrhythmias, NSVT ≥15 PVCs per hour at ≥120 bpm, inadequate arrhythmia suppression in pilot study<br/>
<br/>
### Interventions<br/>
- Randomized to empagliflozin 10 mg, 25 mg, or placebo once daily<br/>
- Background glucose-lowering therapy remained unchanged for 12 weeks post-randomization<br/>
<br/>
### Outcomes<br/>
#### Primary Outcome<br/>
- Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke: 10.5% in the empagliflozin group vs. 12.1% in the placebo group (HR 0.86; 95.02% CI 0.74-0.99; P=0.04)<br/>
<br/>
#### Secondary Outcomes<br/>
- Death from cardiovascular causes: Significantly lower in empagliflozin group (3.7% vs. 5.9%; HR 0.62; P&lt;0.001)<br/>
- Death from any cause: Lower in empagliflozin group (5.7% vs. 8.3%; HR 0.68; P&lt;0.001)<br/>
- Hospitalization for heart failure: Lower in empagliflozin group (2.7% vs. 4.1%; HR 0.65; P=0.002)<br/>
<br/>
### Criticisms<br/>
- The trial was sponsored and designed by the pharmaceutical companies producing empagliflozin.<br/>
- Genital infections were more common in the empagliflozin group.<br/>
<br/>
### Funding<br/>
The study was funded by Boehringer Ingelheim and Eli Lilly.<br/>
<br/>
### Further Reading<br/><br/>
- Supplementary appendix on trial's protocol and statistical analysis plan at NEJM.org
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
